Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer

PET Clin. 2023 Jul;18(3):337-344. doi: 10.1016/j.cpet.2023.02.009. Epub 2023 Apr 6.

Abstract

Like other major cancers, gastric cancer expresses fibroblast activation protein (FAP) in cancer-associated fibroblasts. Many recent studies have reported the utility and superiority of FAP inhibitor (FAPI)-PET over [18F]fluorodeoxyglucose (FDG)-PET in gastric cancers, from initial staging to recurrence detection. FAPI-PET shows higher accumulation in primary sites and metastatic lesions than does FDG-PET, especially for the detection of peritoneal carcinomatosis. In the case of gastric signet ring cell carcinoma, FAPI-PET showed excellent performance, as uptake is usually weak on FDG-PET in this cohort.

Keywords: Fibroblast activation protein; Gastric cancer; Positron emission tomography.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18 / metabolism
  • Humans
  • Peritoneal Neoplasms / diagnostic imaging
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron Emission Tomography Computed Tomography* / trends
  • Positron-Emission Tomography / methods
  • Protease Inhibitors / metabolism
  • Radiopharmaceuticals / metabolism
  • Radiopharmaceuticals / standards
  • Stomach Neoplasms* / diagnostic imaging

Substances

  • Protease Inhibitors
  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals